{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:39:51Z","timestamp":1792517991874,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H03355 to TH"],"award-info":[{"award-number":["21H03355 to TH"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The antidiabetic drug pioglitazone ameliorates insulin resistance by activating the transcription factor PPAR\u03b3. In addition to its blood glucose\u2013lowering action, pioglitazone exerts pleiotropic effects including amelioration of nonalcoholic fatty liver disease (NAFLD)\/nonalcoholic steatohepatitis (NASH). The mechanism by which pioglitazone achieves this latter effect has remained unclear, however. We here show that pioglitazone administration increases the amount of linoleic acid (LA) metabolites in adipose tissue of KK-Ay mice. These metabolites are produced by lactic acid bacteria in the gut, and pioglitazone also increased the fraction of\n                    <jats:italic>Lactobacillus<\/jats:italic>\n                    in the gut microbiota. Administration of the LA metabolite HYA (10-hydroxy-cis-12-octadecenoic acid) to C57BL\/6\u00a0J mice fed a high-fat diet improved liver histology including steatosis, inflammatory cell infiltration, and fibrosis. Gene ontology analysis of RNA-sequencing data for the liver revealed that the top category for genes downregulated by HYA treatment was related to extracellular matrix, and the expression of individual genes related to fibrosis was confirmed to be attenuated by HYA treatment. Mechanistically, HYA suppressed TGF-\u03b2\u2013induced Smad3 phosphorylation and fibrosis-related gene expression in human hepatic stellate cells (LX-2). Our results implicate LA metabolites in the mechanism by which pioglitazone ameliorates liver fibrosis, and they suggest that HYA is a potential therapeutic for NAFLD\/NASH.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-46404-5","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T07:02:27Z","timestamp":1698994947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["A gut microbial metabolite of linoleic acid ameliorates liver fibrosis by inhibiting TGF-\u03b2 signaling in hepatic stellate cells"],"prefix":"10.1038","volume":"13","author":[{"given":"Nanaho","family":"Kasahara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Imi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reina","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusei","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Imamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiaki","family":"Tomimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kunisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigenobu","family":"Kishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Hosooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"key":"46404_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi, Z. et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15, 11\u201320. https:\/\/doi.org\/10.1038\/nrgastro.2017.109 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"46404_CR2","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1001\/jama.2015.5370","volume":"313","author":"ME Rinella","year":"2015","unstructured":"Rinella, M. E. Nonalcoholic fatty liver disease: A systematic review. JAMA 313, 2263\u20132273. https:\/\/doi.org\/10.1001\/jama.2015.5370 (2015).","journal-title":"JAMA"},{"key":"46404_CR3","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","volume":"70","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. Non-alcoholic fatty liver disease-a global public health perspective. J. Hepatol. 70, 531\u2013544. https:\/\/doi.org\/10.1016\/j.jhep.2018.10.033 (2019).","journal-title":"J. Hepatol."},{"key":"46404_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","volume":"92","author":"SA Polyzos","year":"2019","unstructured":"Polyzos, S. A., Kountouras, J. & Mantzoros, C. S. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 92, 82\u201397. https:\/\/doi.org\/10.1016\/j.metabol.2018.11.014 (2019).","journal-title":"Metabolism"},{"key":"46404_CR5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J. Hepatol. 71, 793\u2013801. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.021 (2019).","journal-title":"J. Hepatol."},{"key":"46404_CR6","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1053\/jhep.2003.50161","volume":"37","author":"G Marchesini","year":"2003","unstructured":"Marchesini, G. et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37, 917\u2013923. https:\/\/doi.org\/10.1053\/jhep.2003.50161 (2003).","journal-title":"Hepatology"},{"key":"46404_CR7","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai, P. S. et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology 65, 1557\u20131565. https:\/\/doi.org\/10.1002\/hep.29085 (2017).","journal-title":"Hepatology"},{"key":"46404_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","volume":"129","author":"LA Adams","year":"2005","unstructured":"Adams, L. A. et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 129, 113\u2013121. https:\/\/doi.org\/10.1053\/j.gastro.2005.04.014 (2005).","journal-title":"Gastroenterology"},{"key":"46404_CR9","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.24001","volume":"52","author":"H Tilg","year":"2010","unstructured":"Tilg, H. & Moschen, A. R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 52, 1836\u20131846. https:\/\/doi.org\/10.1002\/hep.24001 (2010).","journal-title":"Hepatology"},{"key":"46404_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17091575","author":"A Caligiuri","year":"2016","unstructured":"Caligiuri, A., Gentilini, A. & Marra, F. Molecular pathogenesis of NASH. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms17091575 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"46404_CR11","doi-asserted-by":"publisher","first-page":"11674","DOI":"10.1073\/pnas.1921015117","volume":"117","author":"T Hosooka","year":"2020","unstructured":"Hosooka, T. et al. The PDK1-FoxO1 signaling in adipocytes controls systemic insulin sensitivity through the 5-lipoxygenase-leukotriene B(4) axis. Proc. Natl. Acad. Sci. USA 117, 11674\u201311684. https:\/\/doi.org\/10.1073\/pnas.1921015117 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"46404_CR12","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","volume":"68","author":"D Schuppan","year":"2018","unstructured":"Schuppan, D., Surabattula, R. & Wang, X. Y. Determinants of fibrosis progression and regression in NASH. J. Hepatol. 68, 238\u2013250. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.012 (2018).","journal-title":"J. Hepatol."},{"key":"46404_CR13","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","volume":"67","author":"H Hagstrom","year":"2017","unstructured":"Hagstrom, H. et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J. Hepatol. 67, 1265\u20131273. https:\/\/doi.org\/10.1016\/j.jhep.2017.07.027 (2017).","journal-title":"J. Hepatol."},{"key":"46404_CR14","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1038\/ncomms3823","volume":"4","author":"I Mederacke","year":"2013","unstructured":"Mederacke, I. et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat. Commun. 4, 2823. https:\/\/doi.org\/10.1038\/ncomms3823 (2013).","journal-title":"Nat. Commun."},{"key":"46404_CR15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"T Tsuchida","year":"2017","unstructured":"Tsuchida, T. & Friedman, S. L. Mechanisms of hepatic stellate cell activation. Nat. Rev. Gastroenterol. Hepatol. 14, 397\u2013411. https:\/\/doi.org\/10.1038\/nrgastro.2017.38 (2017).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"46404_CR16","doi-asserted-by":"publisher","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","volume":"270","author":"JM Lehmann","year":"1995","unstructured":"Lehmann, J. M. et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270, 12953\u201312956. https:\/\/doi.org\/10.1074\/jbc.270.22.12953 (1995).","journal-title":"J. Biol. Chem."},{"key":"46404_CR17","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3389\/fphar.2018.01093","volume":"9","author":"PR Devchand","year":"2018","unstructured":"Devchand, P. R., Liu, T., Altman, R. B., FitzGerald, G. A. & Schadt, E. E. The pioglitazone trek via human PPAR gamma: From discovery to a medicine at the FDA and beyond. Front. Pharmacol. 9, 1093. https:\/\/doi.org\/10.3389\/fphar.2018.01093 (2018).","journal-title":"Front. Pharmacol."},{"key":"46404_CR18","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.2337\/diacare.23.11.1605","volume":"23","author":"S Aronoff","year":"2000","unstructured":"Aronoff, S. et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study. The pioglitazone 001 study group. Diabetes Care 23, 1605\u20131611. https:\/\/doi.org\/10.2337\/diacare.23.11.1605 (2000).","journal-title":"Diabetes Care"},{"key":"46404_CR19","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy, J. A. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 366, 1279\u20131289. https:\/\/doi.org\/10.1016\/S0140-6736(05)67528-9 (2005).","journal-title":"Lancet"},{"key":"46404_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/1479164118825376","volume":"16","author":"RA DeFronzo","year":"2019","unstructured":"DeFronzo, R. A., Inzucchi, S., Abdul-Ghani, M. & Nissen, S. E. Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab. Vasc. Dis. Res. 16, 133\u2013143. https:\/\/doi.org\/10.1177\/1479164118825376 (2019).","journal-title":"Diab. Vasc. Dis. Res."},{"key":"46404_CR21","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","volume":"362","author":"AJ Sanyal","year":"2010","unstructured":"Sanyal, A. J. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675\u20131685. https:\/\/doi.org\/10.1056\/NEJMoa0907929 (2010).","journal-title":"N. Engl. J. Med."},{"key":"46404_CR22","doi-asserted-by":"publisher","first-page":"305","DOI":"10.7326\/M15-1774","volume":"165","author":"K Cusi","year":"2016","unstructured":"Cusi, K. et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial. Ann. Intern. Med. 165, 305\u2013315. https:\/\/doi.org\/10.7326\/M15-1774 (2016).","journal-title":"Ann. Intern. Med."},{"key":"46404_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.diabet.2019.12.007","volume":"46","author":"A Mantovani","year":"2020","unstructured":"Mantovani, A., Byrne, C. D., Scorletti, E., Mantzoros, C. S. & Targher, G. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. Diabetes Metab. 46, 427\u2013441. https:\/\/doi.org\/10.1016\/j.diabet.2019.12.007 (2020).","journal-title":"Diabetes Metab."},{"key":"46404_CR24","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa060326","volume":"355","author":"R Belfort","year":"2006","unstructured":"Belfort, R. et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355, 2297\u20132307. https:\/\/doi.org\/10.1056\/NEJMoa060326 (2006).","journal-title":"N. Engl. J. Med."},{"key":"46404_CR25","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","volume":"135","author":"GP Aithal","year":"2008","unstructured":"Aithal, G. P. et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135, 1176\u20131184. https:\/\/doi.org\/10.1053\/j.gastro.2008.06.047 (2008).","journal-title":"Gastroenterology"},{"key":"46404_CR26","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1002\/hep.25805","volume":"56","author":"LN Bell","year":"2012","unstructured":"Bell, L. N. et al. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: A pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. Hepatology 56, 1311\u20131318. https:\/\/doi.org\/10.1002\/hep.25805 (2012).","journal-title":"Hepatology"},{"key":"46404_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/apt.14111","volume":"46","author":"M Kawaguchi-Suzuki","year":"2017","unstructured":"Kawaguchi-Suzuki, M., Bril, F., Kalavalapalli, S., Cusi, K. & Frye, R. F. Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis. Aliment. Pharmacol. Ther. 46, 56\u201361. https:\/\/doi.org\/10.1111\/apt.14111 (2017).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"46404_CR28","doi-asserted-by":"publisher","first-page":"17808","DOI":"10.1073\/pnas.1312937110","volume":"110","author":"S Kishino","year":"2013","unstructured":"Kishino, S. et al. Polyunsaturated fatty acid saturation by gut lactic acid bacteria affecting host lipid composition. Proc. Natl. Acad. Sci. USA 110, 17808\u201317813. https:\/\/doi.org\/10.1073\/pnas.1312937110 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"46404_CR29","doi-asserted-by":"publisher","first-page":"C39","DOI":"10.1152\/ajpcell.00024.2014","volume":"307","author":"RA Colas","year":"2014","unstructured":"Colas, R. A., Shinohara, M., Dalli, J., Chiang, N. & Serhan, C. N. Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. Am. J. Physiol. Cell Physiol. 307, C39-54. https:\/\/doi.org\/10.1152\/ajpcell.00024.2014 (2014).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"46404_CR30","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/nm1706","volume":"14","author":"T Hosooka","year":"2008","unstructured":"Hosooka, T. et al. Dok1 mediates high-fat diet-induced adipocyte hypertrophy and obesity through modulation of PPAR-gamma phosphorylation. Nat. Med. 14, 188\u2013193. https:\/\/doi.org\/10.1038\/nm1706 (2008).","journal-title":"Nat. Med."},{"key":"46404_CR31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cca.2005.06.014","volume":"364","author":"S Tsukada","year":"2006","unstructured":"Tsukada, S., Parsons, C. J. & Rippe, R. A. Mechanisms of liver fibrosis. Clin. Chim. Acta 364, 33\u201360. https:\/\/doi.org\/10.1016\/j.cca.2005.06.014 (2006).","journal-title":"Clin. Chim. Acta"},{"key":"46404_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.mam.2018.09.002","volume":"65","author":"M Parola","year":"2019","unstructured":"Parola, M. & Pinzani, M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Mol. Aspects Med. 65, 37\u201355. https:\/\/doi.org\/10.1016\/j.mam.2018.09.002 (2019).","journal-title":"Mol. Aspects Med."},{"key":"46404_CR33","doi-asserted-by":"publisher","first-page":"G483","DOI":"10.1152\/ajpgi.00079.2013","volume":"305","author":"JR Clapper","year":"2013","unstructured":"Clapper, J. R. et al. Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. Am. J. Physiol. Gastrointest. Liver Physiol. 305, G483-495. https:\/\/doi.org\/10.1152\/ajpgi.00079.2013 (2013).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"46404_CR34","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.92264","author":"P Lefebvre","year":"2017","unstructured":"Lefebvre, P. et al. Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARalpha-regulated dermatopontin. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.92264 (2017).","journal-title":"JCI Insight"},{"key":"46404_CR35","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo, P. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389\u2013397. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.043 (2015).","journal-title":"Gastroenterology"},{"key":"46404_CR36","doi-asserted-by":"publisher","first-page":"15751","DOI":"10.1074\/jbc.M114.568683","volume":"289","author":"AT Suckow","year":"2014","unstructured":"Suckow, A. T. et al. Alteration of the glucagon axis in GPR120 (FFAR4) knockout mice: A role for GPR120 in glucagon secretion. J. Biol. Chem. 289, 15751\u201315763. https:\/\/doi.org\/10.1074\/jbc.M114.568683 (2014).","journal-title":"J. Biol. Chem."},{"key":"46404_CR37","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1038\/s41467-019-11978-0","volume":"10","author":"J Miyamoto","year":"2019","unstructured":"Miyamoto, J. et al. Gut microbiota confers host resistance to obesity by metabolizing dietary polyunsaturated fatty acids. Nat. Commun. 10, 4007. https:\/\/doi.org\/10.1038\/s41467-019-11978-0 (2019).","journal-title":"Nat. Commun."},{"key":"46404_CR38","doi-asserted-by":"publisher","first-page":"bnaa004","DOI":"10.1210\/endrev\/bnaa004","volume":"41","author":"M Bluher","year":"2020","unstructured":"Bluher, M. Metabolically healthy obesity. Endocr. Rev. 41, bnaa004. https:\/\/doi.org\/10.1210\/endrev\/bnaa004 (2020).","journal-title":"Endocr. Rev."},{"key":"46404_CR39","doi-asserted-by":"publisher","first-page":"E506","DOI":"10.1152\/ajpendo.00586.2009","volume":"299","author":"N Kloting","year":"2010","unstructured":"Kloting, N. et al. Insulin-sensitive obesity. Am. J. Physiol. Endocrinol. Metab. 299, E506-515. https:\/\/doi.org\/10.1152\/ajpendo.00586.2009 (2010).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"46404_CR40","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.bbrc.2015.02.154","volume":"459","author":"T Goto","year":"2015","unstructured":"Goto, T. et al. 10-oxo-12(Z)-octadecenoic acid, a linoleic acid metabolite produced by gut lactic acid bacteria, potently activates PPARgamma and stimulates adipogenesis. Biochem. Biophys. Res. Commun. 459, 597\u2013603. https:\/\/doi.org\/10.1016\/j.bbrc.2015.02.154 (2015).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"46404_CR41","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2337\/diabetes.47.4.507","volume":"47","author":"BM Spiegelman","year":"1998","unstructured":"Spiegelman, B. M. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes 47, 507\u2013514. https:\/\/doi.org\/10.2337\/diabetes.47.4.507 (1998).","journal-title":"Diabetes"},{"key":"46404_CR42","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1172\/JCI1235","volume":"101","author":"A Okuno","year":"1998","unstructured":"Okuno, A. et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest. 101, 1354\u20131361. https:\/\/doi.org\/10.1172\/JCI1235 (1998).","journal-title":"J. Clin. Invest."},{"key":"46404_CR43","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.1210\/jc.2004-0190","volume":"89","author":"Y Miyazaki","year":"2004","unstructured":"Miyazaki, Y. et al. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 89, 4312\u20134319. https:\/\/doi.org\/10.1210\/jc.2004-0190 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"46404_CR44","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1158\/1940-6207.CAPR-17-0296","volume":"11","author":"M Miyazawa","year":"2018","unstructured":"Miyazawa, M. et al. Pioglitazone inhibits periprostatic white adipose tissue inflammation in obese mice. Cancer Prev. Res. (Phila) 11, 215\u2013226. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-17-0296 (2018).","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"46404_CR45","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1136\/gut.2006.093484","volume":"55","author":"L Dubuquoy","year":"2006","unstructured":"Dubuquoy, L. et al. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 55, 1341\u20131349. https:\/\/doi.org\/10.1136\/gut.2006.093484 (2006).","journal-title":"Gut"},{"key":"46404_CR46","doi-asserted-by":"publisher","first-page":"154338","DOI":"10.1016\/j.metabol.2020.154338","volume":"114","author":"A Christofides","year":"2021","unstructured":"Christofides, A., Konstantinidou, E., Jani, C. & Boussiotis, V. A. The role of peroxisome proliferator-activated receptors (PPAR) in immune responses. Metabolism 114, 154338. https:\/\/doi.org\/10.1016\/j.metabol.2020.154338 (2021).","journal-title":"Metabolism"},{"key":"46404_CR47","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s10753-019-01138-3","volume":"43","author":"Y Huang","year":"2020","unstructured":"Huang, Y. et al. Pioglitazone attenuates experimental colitis-associated hyperalgesia through improving the intestinal barrier dysfunction. Inflammation 43, 568\u2013578. https:\/\/doi.org\/10.1007\/s10753-019-01138-3 (2020).","journal-title":"Inflammation"},{"key":"46404_CR48","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/01.mib.0000160770.94199.9b","volume":"11","author":"KL Schaefer","year":"2005","unstructured":"Schaefer, K. L. et al. Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflamm. Bowel Dis. 11, 244\u2013252. https:\/\/doi.org\/10.1097\/01.mib.0000160770.94199.9b (2005).","journal-title":"Inflamm. Bowel Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46404-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46404-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46404-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T07:03:06Z","timestamp":1698994986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46404-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["46404"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-46404-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3323332\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,3]]},"assertion":[{"value":"4 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18983"}}